|drug3281||Suspension of heat killed (autoclaved) Mycobacterium w Wiki||0.58|
|D009164||Mycobacterium Infections NIH||0.50|
|D016638||Critical Illness NIH||0.13|
There is one clinical trial.
The aim of this study is to evaluate the prevalence of COVID-19 among the workers of our hospital and the factors that are likely to influence this prevalence. It must be underlined that our hospital is settled in two towns and both hospital sites had different missions regarding the admissions of COVID-19-infected patients.
Description: measures the prevalence of COVID-19 among the healthcare workers of the Centre Hospitalier Sud Essonne, defined as the hospital employees with positive serologic or RT-PCR tests. It must be underlined that the notion of "health workers" include the entire hospital staff ie doctors, nurses, administrative employees,...Measure: General prevalence of COVID-19 Time: Through study completion, an average of 9 months
Description: no RT PCR or negative RT PCR and positive serologic test, positive RT PCR and no symptoms,Measure: Number of asymptomatic healthcare workers Time: Through study completion, an average of 9 months
Description: Positive RT-PCR test or serologic test with symptoms.Measure: Number of symptomatic healthcare workers Time: Through study completion, an average of 9 months
Description: Positive serologic or RTC-PCR test and hospitalizationMeasure: Number of healthcare workers with a severe form of COVID-19 which led to an hospitalization Time: Through study completion, an average of 9 months
Description: Positive serologic or RTC-PCR test and hospitalization in a critical care unitMeasure: Number of healthcare workers infected with COVID-19 and hospitalized in a critical care unit Time: Through study completion, an average of 9 months
Description: age, gender, job, duration of employment in the hospital, hospital site of affectation, unit of affectation.Measure: Influencing factors of the prevalence of the COVID-19 among healthcare workers Time: Through study completion, an average of 9 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports